RemeGen Co., Ltd. (HKG:9995)
Hong Kong
· Delayed Price · Currency is HKD 88.35
-1.35 (-1.51%)
At close: Dec 5, 2025
RemeGen Revenue
RemeGen had revenue of 621.88M CNY in the quarter ending September 30, 2025, with 33.13% growth. This brings the company's revenue in the last twelve months to 2.23B, up 46.34% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
2.23B CNY
Revenue Growth
+46.34%
P/S Ratio
22.78
Revenue / Employee
742.85K CNY
Employees
2,999
Market Cap
55.46B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |